Younger Lung Cancer Patients Show More Targetable Gene Alterations, Supporting Broader Genomic Profiling

Younger adults with non-small cell lung cancer (搜索)搜索该疾病 (NSCLC) are significantly more likely than older patients to have tumors with genetic alterations that can be matched to targeted therapies, according to a large international study led in part by researchers at Sylvester Comprehensive Cancer Center (搜索)搜索该词条, part of the University of Miami Miller School of Medicine. Analyzing genomic and immune data from 14,246 patients, researchers from Sylvester, Labcorp (搜索)搜索该公司, and Dana-Farber Cancer Institute查看公司主页 found nearly 58% of younger patients had guideline-recommended actionable alterations, compared with about 45% of patients age 55 and older.

The findings will be presented Sept. 14 in Seoul, Republic of Korea, at the 2026 World Conference on Lung Cancer.

Age-Related Differences in Tumor Biology

The study revealed distinct molecular patterns between younger and older patients. Younger patients were more likely to have alterations in ALK (搜索)搜索该靶点, ROS1 (搜索)搜索该靶点, and EGFR (搜索)搜索该靶点 genes—mutations for which well-established targeted therapies exist and can produce dramatic and durable responses. In contrast, older patients' tumors were more likely to have KRAS (搜索)搜索该靶点-related changes, which have historically been harder to target, as well as a higher tumor mutational burden, meaning the cancer carried more mutations overall.

Researchers also found age-related differences in immune markers, including LAG3 (搜索)搜索该靶点 and TIGIT (搜索)搜索该靶点, which are being studied as possible targets for future immunotherapy strategies.

The findings point to a gradual shift in tumor biology with age, rather than a hard divide between younger and older patients. The researchers also observed consistent age-related patterns across multiple ancestry groups, strengthening the evidence that age may influence the molecular drivers of lung cancer.

Implications for Precision Medicine

"As precision medicine continues to evolve, we need to think beyond identifying individual mutations and begin understanding the broader biologic context in which those mutations occur," said Chinmay T. Jani, M.D., medical oncologist at Sylvester and lead author of the study. "Our findings suggest that age may be an important piece of that puzzle. By better understanding how tumors change across the lifespan, we can continue refining how we interpret biomarkers, develop new therapies and personalize treatment strategies for patients with lung cancer."

"Age should be considered alongside traditional biomarkers when evaluating treatment options for patients with lung cancer," said Gilberto Lopes, M.D., Sylvester's chief of medical oncology, associate director and medical director for international affairs and senior author of the study. "As we learn more about the factors that influence how individual tumors behave, we can make more informed treatment decisions and continue advancing truly personalized cancer care."

The study supports broader use of comprehensive genomic profiling, especially for younger adults diagnosed with non-small cell lung cancer (搜索)搜索该疾病, the most common type of lung cancer. Testing can help doctors identify whether a tumor has a genetic driver that may respond to a targeted therapy.

Screening and Early Detection Considerations

Younger adults generally fall outside current lung cancer screening eligibility criteria. The researchers note that research like this can help identify high-risk populations and inform future efforts to expand or refine screening guidelines to support earlier detection.

The results add to growing evidence that precision medicine should account not only for what mutations are present, but also for how tumor biology changes over a patient's lifetime. Age may help explain why lung cancers behave differently from one patient to another, and the findings could help researchers refine how doctors interpret biomarkers and choose more individualized treatment strategies.